Search

Your search keyword '"de Gruijl, Tanja D."' showing total 1,075 results
Start Over Author "de Gruijl, Tanja D."
1,075 results on '"de Gruijl, Tanja D."'

1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

Author

Leek, Lindsay V. M., Notohardjo, Jessica C. L., de Joode, Karlijn, Velker, Eline L., Haanen, John B. A. G., Suijkerbuijk, Karijn P. M., Aarts, Maureen J. B., de Groot, Jan Willem B., Kapiteijn, Ellen, van den Berkmortel, Franchette W. P. J., Westgeest, Hans M., de Gruijl, Tanja D., Retel, Valesca P., Cuppen, Edwin, van der Veldt, Astrid A. M., Labots, Mariette, Voest, Emile E., van de Haar, Joris, and van den Eertwegh, Alfons J. M.

Published
2024
Full Text
View/download PDF

5. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial

Author

Timmer, Florentine E F, Geboers, Bart, Ruarus, Alette H, Vroomen, Laurien G P H, Schouten, Evelien A C, van der Lei, Susan, Vos, Danielle J W, Dijkstra, Madelon, Schulz, Hannah H, Bakker, Joyce, van den Bemd, Bente A T, van den Tol, Petrousjka M, Puijk, Robbert S, Lissenberg-Witte, Birgit I, de Gruijl, Tanja D, de Vries, Jan J J, Lagerwaard, Frank J, Scheffer, Hester J, Bruynzeel, Anna M E, and Meijerink, Martijn R

Published
2024
Full Text
View/download PDF

7. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy

Author

Nowak-Sliwinska, Patrycja, van Beijnum, Judy R., Griffioen, Christian J., Huinen, Zowi R., Sopesens, Nadine Grima, Schulz, Ralph, Jenkins, Samir V., Dings, Ruud P. M., Groenendijk, Floris H., Huijbers, Elisabeth J. M., Thijssen, Victor L. J. L., Jonasch, Eric, Vyth-Dreese, Florry A., Jordanova, Ekaterina S., Bex, Axel, Bernards, René, de Gruijl, Tanja D., and Griffioen, Arjan W.

Published
2023
Full Text
View/download PDF

8. Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival

Author

Timmer, Florentine E.F., Geboers, Bart, Scheffer, Hester J., Bakker, Joyce, Ruarus, Alette H., Dijkstra, Madelon, van der Lei, Susan, Boon, Rianne, Nieuwenhuizen, Sanne, van den Bemd, Bente A.T., Schouten, Evelien A.C., van den Tol, Petrousjka M., Puijk, Robbert S., de Vries, Jan J.J., de Gruijl, Tanja D., and Meijerink, Martijn R.

Published
2023
Full Text
View/download PDF

10. A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies

Author

Lameris, Roeland, Ruben, Jurjen M., Iglesias-Guimarais, Victoria, de Jong, Milon, Veth, Myrthe, van de Bovenkamp, Fleur S., de Weerdt, Iris, Kater, Arnon P., Zweegman, Sonja, Horbach, Sjeng, Riedl, Thilo, Winograd, Benjamin, Roovers, Rob C., Adang, Anton E.P., de Gruijl, Tanja D., Parren, Paul W.H.I., and van der Vliet, Hans J.

Published
2023
Full Text
View/download PDF

12. Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.

Author

King, Lisa A., de Jong, Milon, Veth, Myrthe, Hulsik, David Lutje, Yousefi, Parsa, Iglesias-Guimarais, Victoria, van Helden, Pauline M., de Gruijl, Tanja D., and van der Vliet, Hans J.

Subjects
BISPECIFIC antibodies, CELL populations, CANCER cells, TUMOR antigens, IMMUNE response
Abstract

Background: Vγ9Vδ2 T-cells are antitumor immune effector cells that can detect metabolic dysregulation in cancer cells through phosphoantigen-induced conformational changes in the butyrophilin (BTN) 2A1/3A1 complex. In order to clinically exploit the anticancer properties of Vγ9Vδ2 T-cells, various approaches have been studied including phosphoantigen stimulation, agonistic BTN3A-specific antibodies, adoptive transfer of expanded Vγ9Vδ2 T-cells, and more recently bispecific antibodies. While Vγ9Vδ2 T-cells constitute a sizeable population, typically making up ~1-10% of the total T cell population, lower numbers have been observed with increasing age and in the context of disease. Methods: We evaluated whether bivalent single domain antibodies (VHHs) that link Vδ2-TCR specific VHHs with different affinities could support Vγ9Vδ2 T-cell expansion and could be incorporated in a bispecific engager format when additionally linked to a tumor antigen specific VHH. Results: Bivalent VHHs that link a high and low affinity Vδ2-TCR specific VHH can support Vγ9Vδ2 T-cell expansion. The majority of Vγ9Vδ2 T-cells that expanded following exposure to these bivalent VHHs had an effector or central memory phenotype and expressed relatively low levels of PD-1. Bispecific engagers that incorporated the bivalent Vδ2-TCR specific VHH as well as a tumor antigen specific VHH triggered antitumor effector functions and supported expansion of Vγ9Vδ2 T-cells in vitro and in an in vivo model in NOG-hIL-15 mice. Conclusion: By enhancing the number of Vγ9Vδ2 T-cells available to exert antitumor effector functions, these novel Vδ2-bivalent bispecific T cell engagers may promote the overall efficacy of bispecific Vγ9Vδ2 T-cell engagement, particularly in patients with relatively low levels of Vγ9Vδ2 T-cells. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.

Author

Berthe, Julie, Poudel, Pawan, Segerer, Felix J., Jennings, Emily C., Ng, Felicia, Surace, Michael, Andoni, Alma, Testori, Marco, Saraiya, Megha, Vuko, Miljenka, Hessel, Harald, Heininen-Brown, Mari, Blando, Jorge, Jones, Emma V., Willis, Sophie E., Galon, Jérôme, van de Ven, Rieneke, de Gruijl, Tanja D., and Angell, Helen K.

Subjects
FOLLICULAR dendritic cells, LYMPHOID tissue, B cells, PROGNOSIS, TERTIARY structure
Abstract

Tertiary Lymphoid Structures (TLS) are lymphoid structures commonly associated with improved survival of cancer patients and response to immunotherapies. However, conflicting reports underscore the need to consider TLS heterogeneity and multiple features such as TLS size, composition, and maturation status, when assessing their functional impact. With the aim of gaining insights into TLS biology and evaluating the prognostic impact of TLS maturity in Non-Small Cell Lung Carcinoma (NSCLC), we developed a multiplex immunofluorescent (mIF) panel including T cell (CD3, CD8), B cell (CD20), Follicular Dendritic cell (FDC) (CD21, CD23) and mature dendritic cell (DC-LAMP) markers. We deployed this panel across a cohort of primary tumor resections from NSCLC patients (N=406) and established a mIF image analysis workstream to specifically detect TLS structures and evaluate the density of each cell phenotype. We assessed the prognostic significance of TLS size, number, and composition, to develop a TLS scoring system representative of TLS biology within a tumor. TLS relative area, (total TLS area divided by the total tumor area), was the most prognostic TLS feature (C-index: 0.54, p = 0.04). CD21 positivity was a marker driving the favorable prognostic impact, where CD21+ CD23- B cells (C-index: 0.57, p = 0.04) and CD21+ CD23- FDC (C-index: 0.58, p = 0.01) were the only prognostic cell phenotypes in TLS. Combining the three most robust prognostic TLS features: TLS relative area, the density of B cells, and FDC CD21+ CD23- we generated a TLS scoring system that demonstrated strong prognostic value in NSCLC when considering the effect of age, sex, histology, and smoking status. This TLS Score also demonstrated significant association with Immunoscore, EGFR mutational status and gene expression-based B-cell and TLS signature scores. It was not correlated with PD-L1 status in tumor cells or immune cells. In conclusion, we generated a prognostic TLS Score representative of the TLS heterogeneity and maturity undergoing within NSCLC tissues. This score could be used as a tool to explore how TLS presence and maturity impact the organization of the tumor microenvironment and support the discovery of spatial biomarker surrogates of TLS maturity, that could be used in the clinic. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

Author

Hoeijmakers, Lotte L., primary, Kuijpers, Anke M.J., additional, van de Wiel, Bart A., additional, Lopez-Yurda, Marta I., additional, Plasmeijer, Elsemieke I, additional, Zuur, Charlotte L., additional, van der Pol, Hanna C., additional, Lucas, Minke W., additional, Romano, Jurriaan, additional, Lijnsvelt, Judith, additional, van den Eertwegh, Alfonsus Johannes Maria, additional, Jalving, Mathilde, additional, Kapiteijn, Ellen, additional, Suijkerbuijk, Karijn, additional, Van Der Veldt, Astrid Aplonia Maria, additional, Jacobs, Bart, additional, de Gruijl, Tanja D, additional, and Blank, Christian U., additional

Published
2024
Full Text
View/download PDF

15. Selective tumor antigen vaccine delivery to human CD169+ antigen-presenting cells using ganglioside-liposomes

Author

Affandi, Alsya J., Grabowska, Joanna, Olesek, Katarzyna, Venegas, Miguel Lopez, Barbaria, Arnaud, Rodríguez, Ernesto, Mulder, Patrick P. G., Pijffers, Helen J., Ambrosini, Martino, Kalay, Hakan, O’Toole, Tom, Zwart, Eline S., Kazemier, Geert, Nazmi, Kamran, Bikker, Floris J., Stöckl, Johannes, van den Eertwegh, Alfons J. M., de Gruijl, Tanja D., Storm, Gert, van Kooyk, Yvette, and den Haan, Joke M. M.

Published
2020

16. Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer

Author

Bakkerus, Lotte, Subtil, Beatriz, Bontkes, Hetty J., Gootjes, Elske C., Reijm, Martine, Vullings, Manon, Verrijp, Kiek, Bokhorst, John Melle, Woortman, Carmen, Nagtegaal, Iris D., Jonker, Marianne A., van der Vliet, Hans J., Verhoef, Cornelis, Gorris, Mark A.J., de Vries, I. Jolanda M., de Gruijl, Tanja D., Verheul, Henk M.W., Buffart, Tineke E., Tauriello, Daniele V.F., Bakkerus, Lotte, Subtil, Beatriz, Bontkes, Hetty J., Gootjes, Elske C., Reijm, Martine, Vullings, Manon, Verrijp, Kiek, Bokhorst, John Melle, Woortman, Carmen, Nagtegaal, Iris D., Jonker, Marianne A., van der Vliet, Hans J., Verhoef, Cornelis, Gorris, Mark A.J., de Vries, I. Jolanda M., de Gruijl, Tanja D., Verheul, Henk M.W., Buffart, Tineke E., and Tauriello, Daniele V.F.

Abstract

Colorectal cancer (CRC) raises considerable clinical challenges, including a high mortality rate once the tumor spreads to distant sites. At this advanced stage, more accurate prediction of prognosis and treatment outcome is urgently needed. The role of cancer immunity in metastatic CRC (mCRC) is poorly understood. Here, we explore cellular immune cell status in patients with multi-organ mCRC. We analyzed T cell infiltration in primary tumor sections, surveyed the lymphocytic landscape of liver metastases, and assessed circulating mononuclear immune cells. Besides asking whether immune cells are associated with survival at this stage of the disease, we investigated correlations between the different tissue types; as this could indicate a dominant immune phenotype. Taken together, our analyses corroborate previous observations that higher levels of CD8+ T lymphocytes link to better survival outcomes. Our findings therefore extend evidence from earlier stages of CRC to indicate an important role for cancer immunity in disease control even after metastatic spreading to multiple organs. This finding may help to improve predicting outcome of patients with mCRC and suggests a future role for immunotherapeutic strategies.

Published
2024

17. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

Author

MS Medische Oncologie, Cancer, Infection & Immunity, CMM Groep Van Mil, Leek, Lindsay V M, Notohardjo, Jessica C L, de Joode, Karlijn, Velker, Eline L, Haanen, John B A G, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, de Groot, Jan Willem B, Kapiteijn, Ellen, van den Berkmortel, Franchette W P J, Westgeest, Hans M, de Gruijl, Tanja D, Retel, Valesca P, Cuppen, Edwin, van der Veldt, Astrid A M, Labots, Mariette, Voest, Emile E, van de Haar, Joris, van den Eertwegh, Alfons J M, MS Medische Oncologie, Cancer, Infection & Immunity, CMM Groep Van Mil, Leek, Lindsay V M, Notohardjo, Jessica C L, de Joode, Karlijn, Velker, Eline L, Haanen, John B A G, Suijkerbuijk, Karijn P M, Aarts, Maureen J B, de Groot, Jan Willem B, Kapiteijn, Ellen, van den Berkmortel, Franchette W P J, Westgeest, Hans M, de Gruijl, Tanja D, Retel, Valesca P, Cuppen, Edwin, van der Veldt, Astrid A M, Labots, Mariette, Voest, Emile E, van de Haar, Joris, and van den Eertwegh, Alfons J M

Published
2024

18. The immunoregulatory role of monocytes and thrombomodulin in myelodysplastic neoplasms.

Author

Janssen, Luca L. G., van Leeuwen-Kerkhoff, Nathalie, Westers, Theresia M., de Gruijl, Tanja D., and van de Loosdrecht, Arjan A.

Subjects
BONE marrow, NATURAL immunity, THROMBOMODULIN, MONOCYTES, BIOLOGY
Abstract

Myelodysplastic neoplasms (MDS) are clonal disorders of the myeloid lineage leading to peripheral blood cytopenias. Dysregulation of innate immunity is hypothesized to be a potent driver of MDS. A recent study revealed increased thrombomodulin (TM) expression on classical monocytes in MDS, which was associated with prolonged survival. TM is a receptor with immunoregulatory capacities, however, its exact role in MDS development remains to be elucidated. In this review we focus on normal monocyte biology and report on the involvement of monocytes in myeloid disease entities with a special focus on MDS. Furthermore, we delve into the current knowledge on TM and its function in monocytes in health and disease and explore the role of TM-expressing monocytes as driver, supporter or epiphenomenon in the MDS bone marrow environment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET

Author

Pouw, Johanna E E, primary, Hashemi, Sayed M S, additional, Huisman, Marc C, additional, Wijngaarden, Jessica E, additional, Slebe, Maarten, additional, Oprea-Lager, Daniela E, additional, Zwezerijnen, Gerben J C, additional, Vugts, Danielle, additional, Ulas, Ezgi B, additional, de Gruijl, Tanja D, additional, Radonic, Teodora, additional, Senan, Suresh, additional, Menke-van der Houven van Oordt, C Willemien, additional, and Bahce, Idris, additional

Published
2024
Full Text
View/download PDF

23. A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response

Author

Lameris, Roeland, Shahine, Adam, Pellicci, Daniel G., Uldrich, Adam P., Gras, Stephanie, Le Nours, Jérôme, Groen, Richard W. J., Vree, Jana, Reddiex, Scott J. J., Quiñones-Parra, Sergio M., Richardson, Stewart K., Howell, Amy R., Zweegman, Sonja, Godfrey, Dale I., de Gruijl, Tanja D., Rossjohn, Jamie, and van der Vliet, Hans J.

Published
2020
Full Text
View/download PDF

27. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, and Long, Georgina V

Published
2019
Full Text
View/download PDF

28. Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-Cells.

Author

de Haas, Aram M., Stolk, Dorian A., Schetters, Sjoerd T. T., Goossens-Kruijssen, Laura, Keuning, Eelco, Ambrosini, Martino, Boon, Louis, Kalay, Hakan, Storm, Gert, van der Vliet, Hans J., de Gruijl, Tanja D., and van Kooyk, Yvette

Subjects
T cells, PEPTIDOMIMETICS, CANCER vaccines, KILLER cells, VACCINATION
Abstract

Cancer vaccines have emerged as a potent strategy to improve cancer immunity, with or without the combination of checkpoint blockade. In our investigation, liposomal formulations containing synthetic long peptides and α-Galactosylceramide, along with a DC-SIGN-targeting ligand, Lewis Y (LeY), were studied for their anti-tumor potential. The formulated liposomes boosted with anti-CD40 adjuvant demonstrated robust invariant natural killer (iNKT), CD4+, and CD8+ T-cell activation in vivo. The incorporation of LeY facilitated the targeting of antigen-presenting cells expressing DC-SIGN in vitro and in vivo. Surprisingly, mice vaccinated with LeY-modified liposomes exhibited comparable tumor reduction and survival rates to those treated with untargeted counterparts despite a decrease in antigen-specific CD8+ T-cell responses. These results suggest that impaired induction of antigen-specific CD8+ T-cells via DC-SIGN targeting does not compromise anti-tumor potential, hinting at alternative immune activation routes beyond CD8+ T-cell activation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.

Author

Groen-van Schooten, Tessa S., Harrasser, Micaela, Seidel, Jens, Bos, Emma N., Fleitas, Tania, van Mourik, Monique, Pouw, Roos E., Goedegebuure, Ruben S. A., Doeve, Benthe H., Sanders, Jasper, Bos, Joris, van Berge Henegouwen, Mark I., Thijssen, Victor L. J. L., van Grieken, Nicole C. T., van Laarhoven, Hanneke W. M., de Gruijl, Tanja D., and Derks, Sarah

Subjects
ESOPHAGEAL tumors, MYELOID-derived suppressor cells, IMMUNOSUPPRESSION, ADENOCARCINOMA, T cells
Abstract

Background: Tumors in the distal esophagus (EAC), gastro-esophageal junction including cardia (GEJAC), and stomach (GAC) develop in close proximity and show strong similarities on a molecular and cellular level. However, recent clinical data showed that the effectiveness of chemo-immunotherapy is limited to a subset of GEAC patients and that EACs and GEJACs generally benefit less from checkpoint inhibition compared to GACs. As the composition of the tumor immune microenvironment drives response to (immuno)therapy we here performed a detailed immune analysis of a large series of GEACs to facilitate the development of a more individualized immunomodulatory strategy. Methods: Extensive immunophenotyping was performed by 14-color flow cytometry in a prospective study to detail the immune composition of untreated gastro-esophageal cancers (n=104) using fresh tumor biopsies of 35 EACs, 38 GEJACs and 31 GACs. The immune cell composition of GEACs was characterized and correlated with clinicopathologic features such as tumor location, MSI and HER2 status. The spatial immune architecture of a subset of tumors (n=30) was evaluated using multiplex immunohistochemistry (mIHC) which allowed us to determine the tumor infiltration status of CD3+, CD8+, FoxP3+, CD163+ and Ki67+ cells. Results: Immunophenotyping revealed that the tumor immune microenvironment of GEACs is heterogeneous and that immune suppressive cell populations such as monocytic myeloid-derived suppressor cells (mMDSC) are more abundant in EACs compared to GACs (p<0.001). In contrast, GACs indicated a proinflammatory microenvironment with elevated frequencies of proliferating (Ki67+) CD4 Th cells (p<0.001), Ki67+ CD8 T cells (p=0.002), and CD8 effector memory-T cells (p=0.024). Differences between EACs and GACs were confirmed by mIHC analyses showing lower densities of tumor- and stroma-infiltrating Ki67+ CD8 T cells in EAC compared to GAC (both p=0.021). Discussions: This comprehensive immune phenotype study of a large series of untreated GEACs, identified that tumors with an esophageal tumor location have more immune suppressive features compared to tumors in the gastro-esophageal junction or stomach which might explain the location-specific responses to checkpoint inhibitors in this disease. These findings provide an important rationale for stratification according to tumor location in clinical studies and the development of location-dependent immunomodulatory treatment approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Author

Werter, Inge M., Huijts, Charlotte M., Lougheed, Sinéad. M., Hamberg, Paul, Polee, Marco B., Tascilar, Metin, Los, Maartje, Haanen, John B. A. G., Helgason, Helgi H., Verheul, Henk M., de Gruijl, Tanja D., van der Vliet, Hans J., and for the Dutch WIN-O Consortium

Published
2019
Full Text
View/download PDF

42. Supplementary Figures from A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

Author

King, Lisa A., primary, Toffoli, Elisa C., primary, Veth, Myrthe, primary, Iglesias-Guimarais, Victoria, primary, Slot, Manon C., primary, Amsen, Derk, primary, van de Ven, Rieneke, primary, Derks, Sarah, primary, Fransen, Marieke F., primary, Tuynman, Jurriaan B., primary, Riedl, Thilo, primary, Roovers, Rob C., primary, Adang, Anton E.P., primary, Ruben, Jurjen M., primary, Parren, Paul W.H.I., primary, de Gruijl, Tanja D., primary, and van der Vliet, Hans J., primary

Published
2023
Full Text
View/download PDF

43. Data from A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

Author

King, Lisa A., primary, Toffoli, Elisa C., primary, Veth, Myrthe, primary, Iglesias-Guimarais, Victoria, primary, Slot, Manon C., primary, Amsen, Derk, primary, van de Ven, Rieneke, primary, Derks, Sarah, primary, Fransen, Marieke F., primary, Tuynman, Jurriaan B., primary, Riedl, Thilo, primary, Roovers, Rob C., primary, Adang, Anton E.P., primary, Ruben, Jurjen M., primary, Parren, Paul W.H.I., primary, de Gruijl, Tanja D., primary, and van der Vliet, Hans J., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Tables from A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

Author

King, Lisa A., primary, Toffoli, Elisa C., primary, Veth, Myrthe, primary, Iglesias-Guimarais, Victoria, primary, Slot, Manon C., primary, Amsen, Derk, primary, van de Ven, Rieneke, primary, Derks, Sarah, primary, Fransen, Marieke F., primary, Tuynman, Jurriaan B., primary, Riedl, Thilo, primary, Roovers, Rob C., primary, Adang, Anton E.P., primary, Ruben, Jurjen M., primary, Parren, Paul W.H.I., primary, de Gruijl, Tanja D., primary, and van der Vliet, Hans J., primary

Published
2023
Full Text
View/download PDF

45. Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition

Author

van den Ende, Tom, primary, Ezdoglian, Aiarpi, additional, Baas, Lisanne M., additional, Bakker, Joyce, additional, Lougheed, Sinéad M., additional, Harrasser, Micaela, additional, Waasdorp, Cynthia, additional, van Berge Henegouwen, Mark I., additional, Hulshof, Maarten C.C.M., additional, Haj Mohammad, Nadia, additional, van Hillegersberg, Richard, additional, Mook, Stella, additional, van der Laken, Conny J., additional, van Grieken, Nicole C.T., additional, Derks, Sarah, additional, Bijlsma, Maarten F., additional, van Laarhoven, Hanneke W.M., additional, and de Gruijl, Tanja D., additional

Published
2023
Full Text
View/download PDF

46. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial

Author

Dickhoff, Chris, Senan, Suresh, Schneiders, Famke L., Veltman, Joris, Hashemi, Sayed, Daniels, Johannes M. A., Fransen, Marieke, Heineman, David J., Radonic, Teodora, van de Ven, Peter M., Bartelink, Imke H., Meijboom, Lilian J., Garcia-Vallejo, Juan J., Oprea-Lager, Daniela E., de Gruijl, Tanja D., and Bahce, Idris

Published
2020
Full Text
View/download PDF

47. Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

Author

Olson, Robert, Mathews, Lindsay, Liu, Mitchell, Schellenberg, Devin, Mou, Benjamin, Berrang, Tanya, Harrow, Stephen, Correa, Rohann J. M., Bhat, Vasudeva, Pai, Howard, Mohamed, Islam, Miller, Stacy, Schneiders, Famke, Laba, Joanna, Wilke, Derek, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Gaede, Stewart, Warner, Andrew, de Gruijl, Tanja D., Allan, Alison, and Palma, David A.

Published
2020
Full Text
View/download PDF

49. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors

Author

King, Lisa A., primary, Toffoli, Elisa C., additional, Veth, Myrthe, additional, Iglesias-Guimarais, Victoria, additional, Slot, Manon C., additional, Amsen, Derk, additional, van de Ven, Rieneke, additional, Derks, Sarah, additional, Fransen, Marieke F., additional, Tuynman, Jurriaan B., additional, Riedl, Thilo, additional, Roovers, Rob C., additional, Adang, Anton E.P., additional, Ruben, Jurjen M., additional, Parren, Paul W.H.I., additional, de Gruijl, Tanja D., additional, and van der Vliet, Hans J., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results